Evidence map›Paper›PMID 37576936›Full record

ArticleCurrent opinion in endocrine and metabolic research2023

InTERTwined: how

Iñigo Landa

Open access · greenAbstract read
In one paragraph

Article in Current opinion in endocrine and metabolic research, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
1.4field-weighted citation impact, top 17% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 7 citations in OpenAlex.

  1. Review
  2. Review
  3. Review
  4. Role ofMolecular and clinical oncology · 2025
    Review
  5. Review
  6. Review
  7. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author at 1 institution in 1 country.

Iñigo LandaDivision of Endocrinology, Diabetes and Hypertension, Brigham and Women's Hospital, Boston, MA, USA.
Brigham and Women's Hospital · US

Funding

TERT transcriptional deregulation in thyroid cancer progressionK22CA230381 · NCI · BRIGHAM AND WOMEN'S HOSPITAL · PI LANDA-LOPEZ, INIGO · 2020 to 2022
$587k
NCI NIH HHS K22 CA230381
6 · The paper itself

Abstract

Thyroid cancers are often initiated by the acquisition of a BRAF

Indexed as

biomarkers of cancer progressionBRAFV600Ecancer progressionMAPK pathwayoncogenic BRAFtelomerasetelomerase reverse transcriptaseTERT promoter mutationsthyroid cancer

Identifiers

PMID37576936
PMCPMC10419322
OpenAlexW4378417503

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.